# OnCo record autogene-cevumeran (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/autogene-cevumeran/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "autogene-cevumeran" ;
  schema:name "Autogene cevumeran"@en ;
  schema:description "Autogene cevumeran is BioNTech and Genentech's personalised mRNA vaccine encoding each patient's own tumour neoantigens. In a small phase 1 in resected pancreatic cancer, half of patients mounted T-cell responses and stayed free of recurrence far longer; phase 2 IMCODE003 tests whether that holds."@en ;
  schema:url <https://onco.cc/drugs/autogene-cevumeran/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=BNT122>, <https://doi.org/10.1038/s41586-024-08508-4> ;
  onco:status "phase-2" ;
  onco:modality "Personalised mRNA neoantigen vaccine" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/resectable-pdac/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/melanoma/> ;
  onco:technologies <https://onco.cc/technologies/neoantigen-mrna-vaccine/> ;
  onco:companies <https://onco.cc/companies/biontech/>, <https://onco.cc/companies/roche-genentech/> ;
  onco:trials <https://onco.cc/trials/nct05968326/>, <https://onco.cc/trials/autogene-cevumeran-phase-1/> .